Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.175 AUD | 0.00% | -2.78% | -2.78% |
Apr. 23 | Microba's Revenue Climbs 297% in Fiscal Q3 | MT |
Apr. 10 | Microba Life Sciences Secures AU$6 Million Tax Rebate for Fiscal Year 2023; Shares Fall 5% | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- With an enterprise value anticipated at 4.9 times the sales for the current fiscal year, the company turns out to be overvalued.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-2.78% | 51.75M | - | ||
-16.58% | 8.49B | B+ | ||
+58.90% | 4.08B | C+ | ||
-39.78% | 2.42B | B- | ||
-10.33% | 2.42B | - | ||
-8.91% | 2.33B | B- | ||
-2.53% | 2.01B | C- | ||
-19.90% | 1.53B | A- | ||
-38.30% | 1.26B | C+ | ||
+2.19% | 1.07B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- MAP Stock
- Ratings Microba Life Sciences Limited